Zollinger-Ellison Syndrome Treatment Global Market Report 2024

The global zollinger-ellison syndrome treatment market has grown strongly in recent years. It will grow from $1.28 billion in 2023 to $1.35 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to advancements in gastroenterology, increased incidence of zes, multidisciplinary care teams, long-term monitoring.

The global zollinger-ellison syndrome treatment market is expected to see steady growth in the next few years. It will grow to $1.63 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to global healthcare access, genetic screening and diagnosis, personalized treatment plans, regulatory changes and reimbursement policies. Major trends in the forecast period include advanced imaging and diagnostic tools, tailored medications, patient-centered care, minimally invasive interventions.

The growing incidence of digestive disorders is anticipated to drive the expansion of the Zollinger-Ellison syndrome treatment market in the foreseeable future. Digestive disorders encompass a range of conditions that disrupt the normal functioning of the digestive system, responsible for food breakdown and nutrient absorption. Zollinger-Ellison syndrome (ZES) treatment is employed to manage digestive disorders such as peptic ulcer disease and gastroesophageal reflux disease (GERD). The treatment primarily focuses on reducing stomach acid production, which can aid in the prevention and treatment of complications associated with peptic ulcers or acid reflux. As an example, data from the National Library of Medicine in August 2022 revealed that peptic ulcer disease (PUD) affects four million individuals globally annually, with an estimated lifetime prevalence of 5-10% among the general population. Furthermore, each year, 62 million Americans are diagnosed with various digestive disorders. Consequently, the rising prevalence of digestive disorders is expected to be a driving force for the Zollinger-Ellison syndrome treatment market.

The growing need for non-invasive diagnostic procedures is projected to foster the growth of the Zollinger-Ellison syndrome treatment market in the coming period. Non-invasive diagnostic procedures encompass medical assessments and treatments that do not require physical penetration of the body through natural or artificial openings, or the breaking of the skin. Non-invasive diagnostic procedures can facilitate the early detection of Zollinger-Ellison Syndrome, leading to prompt treatment and improved outcomes. For instance, according to a report by Definitive Healthcare LLC in August 2022, one of the most commonly performed non-invasive vascular study procedures in 2021, with 2.67 million procedures conducted, was the restricted or unilateral duplex scan of extremity veins. The total bilateral duplex scan of extremity veins came second, with over 2.16 million procedures completed in 2021. Hence, the increasing demand for non-invasive diagnostic procedures is a catalyst for the growth of the Zollinger-Ellison syndrome treatment market.

The presence of medication side effects is projected to pose challenges to the growth of the Zollinger-Ellison syndrome treatment market. Medication side effects pertain to unintended and often undesirable outcomes that can occur when individuals take medications to address medical conditions. In the context of Zollinger-Ellison Syndrome (ZES), medications like proton pump inhibitors (PPIs), which are used to manage excessive stomach acid in ZES patients, may lead to side effects such as headaches, diarrhea, and stomach discomfort. Consequently, these medication-related side effects are impeding the growth of the Zollinger-Ellison syndrome treatment market.

Major players within the Zollinger-Ellison syndrome treatment market are dedicated to pioneering new drugs and securing their approvals to bolster their market positions. Existing treatments for ZES can carry significant side effects, including the potential for renal and liver damage. Advanced treatments have the potential to mitigate the adverse effects associated with traditional medications and enhance patient outcomes. For instance, in May 2023, Meitheal Pharmaceuticals Inc., a U.S.-based manufacturer of generic injectable products, introduced Pantoprazole Sodium for Injection at 40 mg per vial. This proton pump inhibitor (PPI) is recommended for individuals with pathological hypersecretory conditions like Zollinger-Ellison (ZE) Syndrome. It works by inhibiting the proton pump enzyme (H+/K+ ATPase) in gastric parietal cells, thereby reducing stomach acid secretion and alleviating ZE syndrome-related symptoms.

In June 2023, Ironwood Pharmaceuticals, a U.S.-based healthcare company with a focus on gastrointestinal (GI) conditions, acquired VectivBio for an estimated $1 billion. This strategic acquisition is poised to strengthen Ironwood's innovation pipeline and portfolio, with the aim of redefining the standard of care for GI patients and advancing the treatment of GI disorders. VectivBio, based in Switzerland, specializes in offering treatments for severe rare gastrointestinal conditions, including ZES.

Major players in the zollinger-ellison syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Shionogi & Company Limited, Cipla Limited, Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories, Accord Healthcare Limited, Ordain Health Care Global Pvt.Ltd., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Biochem Pharmaceuticals Industries Limited.

North America was the largest region in the zollinger-ellison syndrome treatment market in 2023. The regions covered in zollinger-ellison syndrome treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the zollinger-ellison syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Diagnosing Zollinger-Ellison syndrome involves a range of tests, including blood tests, CT scans, ultrasounds, X-rays, and other diagnostic methods. Blood tests, also referred to as blood analyses or blood work, are medical procedures employed to collect and analyze blood samples from patients. The treatment options for Zollinger-Ellison syndrome encompass various modalities, including chemotherapy, surgical resection, and other therapeutic approaches. These treatments are available through multiple distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are utilized by various end users, including hospitals, specialty clinics, and other healthcare facilities.

This report provides zollinger-ellison syndrome treatment market statistics, including zollinger-ellison syndrome treatment industry global market size, regional shares, competitors with a zollinger-ellison syndrome treatment market share, detailed zollinger-ellison syndrome treatment market segments, market trends and opportunities and any further data you may need to thrive in the zollinger-ellison syndrome treatment industry. This zollinger-ellison syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The zollinger-ellison syndrome treatment market consists of revenues earned by entities by providing surgical removal of tumors and gastrin level monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The Zollinger-Ellison syndrome treatment market also includes sales of somatostatin analogs, proton pump inhibitors (PPIs) and gastrin inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.